Home › Cancer (all types) › NCT06423950
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
RecruitingObservational study
Feasibility of Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * Participant must be considered likely incurable given the standard of care. This is inclusive of patients newly diagnosed, relapsed or in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but unlikely curative options for care. The site investigator will make this determination based on their experience. * Participant must have an age-appropriate performance status: Karnofsky 50 or more for patients 16 years of age or older OR Lansky score of 50 or more for patients less than16 years of age. * Participant and/or parents or legal guardian and primary oncologist must be willing to consider the therapeutic strategies recommended by the pedsETB. * Participant must be willing to be followed over time and allow collection of clinical data including scans, available blood and lab samples, and optional pedsETB serial blood sampling. * All Participants and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document. Exclusion Criteria: * Participants without known therapies to reliably induce a response are excluded from pedsETB and should seek clinical trials.
About the study
To evaluate the ability of a multidisciplinary and multisite group, the Pediatric Evolutionary Tumor Board (pedsETB), to develop additional therapeutic strategies in patients without curative options or with suboptimal outcomes.
What is being tested
- Peds Evolutionary Tumor Board (pedsETB) (other)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Participants: 35 · Started: May 1, 2024
Contact the study team
- Jessica Crimella · Phone: 813-745-6250
Official record on ClinicalTrials.gov — NCT06423950
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.